A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

WHO includes ArkBio' paediatric RSV drug, ziresovir in PADO-RSV priority list: Shanghai, China Thursday, July 17, 2025, 14:00 Hrs [IST] Shanghai Ark Biopharmaceutical Co., Ltd. (A ...

Some patients with highly drug-resistant tuberculosis could benefit from a shorter treatment with fewer drugs, while others ...

Testing at India’s National Institute of Virology has confirmed a third recent Nipah virus case from India’s Kerla state, ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...